LSI announced that a domestic clinical trial for spinal cord injury in the subacute phase will be started using the Muse cell product “CL2020”.. The company has been conducting clinical trials already for three other diseases, acute myocardial infarction, cerebral infarction, and epidermolysis bullosa, and aims to apply for approval in 2020 and 2021 for any of the four diseases. Muse cells are pluripotent stem cells discovered by Prof. Mari Dezawa of Tohoku University. They occur in mesenchymal stem cells (MSC) of bone marrow and other organs, and they can differentiate into any ectoderm, mesoderm or endoderm. They can be stored through cryopreservation.
Mitsubishi LSI news release, July 10, 2019